**CASE REPORT**

Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis

Kentaro Ido, Takahiko Nakane, Nao Tanizawa, Yosuke Makuuchi, Hiroshi Okamura, Shiro Koh, Satoru Nanno, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino and Hirohisa Nakamae

**Abstract:**

A 53-year-old man presented with uncontrolled bleeding caused by acquired platelet dysfunction accompanied by calreticulin-mutated primary myelofibrosis. Based on the detection of abnormal platelets, including large gray platelets, under light microscopy and the loss of the second wave of aggregation observed by light transmission aggregometry, the patient was diagnosed with platelet dysfunction accompanied by myeloproliferative neoplasms (MPNs). In addition, the absence of platelet α-granules was confirmed by electron microscopy. Therefore, this condition may be termed “acquired gray platelet syndrome.” Acquired platelet dysfunction must be ruled out when abnormal platelets are observed in patients with MPNs.

**Key words:** acquired platelet dysfunction, primary myelofibrosis (PMF), myeloproliferative neoplasms (MPNs)

(Intern Med 59: 2751-2756, 2020)  
(DOI: 10.2169/internalmedicine.4912-20)

**Introduction**

Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-negative MPNs), including polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal hematopoietic cell disorders characterized by the proliferation of cells of one or more myeloid lineages (1, 2). Patients with Ph-negative MPNs frequently experience thrombotic complications and unexpected bleeding (3, 4) and exhibit the following quantitative and qualitative platelet disorders: acquired von Willebrand syndrome; the administration of aspirin; acquired coagulopathies including liver dysfunction and acquired hemophilia; vascular alterations; platelet dysfunctions due to clonal hematopoiesis; and thrombocytopenia caused by progressive disease, splenomegaly, cytoreductive therapies, and the administration of ruxolitinib (5-7). A platelet function analysis, flow cytometry, and thromboelastography might be useful for diagnosing these disorders (5). However, no tests that effectively screen for the risk of bleeding among Ph-negative MPNs and the treatment for reducing the risk of bleeding have yet been established.

We herein report a case of acquired platelet dysfunction associated with calreticulin (CALR)-mutated PMF that was detected using light microscopy and light transmission aggregometry (LTA).

**Case Report**

A 53-year-old man had been diagnosed with CALR-mutated PMF 2 years before admission and had been monitored carefully without any treatment. However, the patient’s PMF progressed to the intermediate-2 risk category on the basis of the refined dynamic international prognostic scoring system (DIPSS plus) and the accelerated phase according to his level of circulating blastoid cells (Table 1); he also exhibited palpable splenomegaly (2, 8, 9). Therefore, allogeneic hematopoietic cell transplantation (allo-HCT) was indicated. In order to control disease progression, ruxolitinib and hydroxycarbamide administration had been initiated three months before admission. Despite these treatments, he...
required admission to our hospital due to the onset of massive ascites. At the time of admission, 25 mg ruxolitinib was administered twice a day and 1,500 mg hydroxycarbamide once a day; however, no platelet-interfering drugs such as aspirin or clopidogrel had been administered.

Using invasive procedures, we estimated the risk of bleeding to be low at that time because general laboratory examinations did not suggest hemostatic disorders, although the platelet count was slightly below the lower limit of normal (Table 1). The peritoneum was punctured to obtain a peritoneal effusion specimen and reduce the volume of the abdomen both on the day of admission and again five days after admission. At seven days after admission, the patient developed severe anemia (hemoglobin: 5.4 g/dL). A dynamic contrast-enhanced computed tomography scan revealed uncontrolled bleeding of the abdominal wall, which was stopped by embolizing the responsible artery. Furthermore, at 12 days after admission, a central venous catheter was inserted through the right internal jugular vein. However, it became necessary to remove the catheter and suture the hole immediately because of uncontrollable bleeding at the insertion site around the catheter.

Due to these unexpected bleeding episodes, a hemostatic or coagulation disorder was suspected; therefore, various laboratory tests were performed. Detailed laboratory findings are shown in Table 2. The bleeding time was normal, but von Willebrand disease or acquired von Willebrand syndrome (vWD/AvWS) type 2A, 2B, or 2M could not be ruled out because of the low level of von Willebrand factor (vWF):ristocetin cofactor (RCO) and the low vWF:RCO/vWF:antigen ratio (10). In contrast, large gray platelets were observed using May-Giemsa staining under light microscopy (Fig. 1A, B). In LTA (Born’s method), a lag phase of normal duration and a normal level of aggregation (%) were observed with 2.0 μM collagen, and a normal level of aggregation (%) was observed with 1.5 mg/mL ristocetin. However, the loss of the second wave of aggregation and a tendency toward deaggregation was observed with 2.0 μM adenosine diphosphate (ADP) (Fig. 2). Ristocetin-induced platelet aggregation (RIPA) with two fold-diluted ristocetin did not indicate platelet hyperreactivity; therefore, vWD/AvWS type 2B or platelet-type was ruled out (Fig. 3) (10, 11). However, we could not determine the type of vWD/AvWS, such as the type 2A and 2M, because no further vWF multimer analysis was performed, and there was no decrease in RIPA with use of the standard concentration of ristocetin; this decrease is typically seen in type 2A or 2M vWD/AvWS (Fig. 2) (12). Electron microscopy demonstrated that platelets lacked α-granules and contained abundant channels of the open canalicular system (Fig. 1C, D). Therefore, the patient was diagnosed with acquired platelet dysfunction accompanied by PMF.

Table 1. Laboratory Findings upon Admission.

| Periopheral blood | Reference range | Values upon admission |
|-------------------|-----------------|-----------------------|
| White-cell count (μL) | 4,300-8,000 | 16,500 |
| Neutrophils (%) | 39.0 | |
| Immature granulocytes (%) | 3.0 | |
| Eosinophils (%) | 1.0 | |
| Basophils (%) | 12.0 | |
| Lymphocytes (%) | 31.0 | |
| Monocytes (%) | 1.0 | |
| Blastoid cells (%) | 13.0 | |
| Red-cell count (μL) | 4,500,000-5,100,000 | 3,090,000 |
| Reticulocytes (%) | 5-20 | 22.0 |
| Hemoglobin (g/dL) | 12.4-17.2 | 8.0 |
| Hematocrit (%) | 38.0-54.0 | 25.9 |
| Erythroblasts (100 cell count) | 18 | |
| Platelet count (μL) | 180,000-340,000 | 151,000 |
| Prothrombin time (s) | 11.5-14.5 | 13.8 |
| PT-INR | 0.9-1.1 | 1.18 |
| Activated partial-thromboplastin time (s) | 25.0-40.0 | 37.6 |
| Fibrinogen (mg/dL) | 200-400 | 409 |
| FDP (μg/mL) | 0-10.0 | 8.2 |
| WT1 mRNA (copies/μg RNA) | 1100 | |
| JAK2 V617F mutation | (-) | |
| CALR exon9 mutation | (+), type1 (del52) | |
| MPL W515L/K mutation | (-) | |
| G-bandng, peripheral blood | 46, XY, add(12)(q11), del(13)(q?) [3] | 46, XY [17] |

FDP: fibrin and fibrinogen degradation products, PT-INR: prothrombin time international normalized ratio.

**Required reading:**

Intern Med 59: 2751-2756, 2020 DOI: 10.2169/internalmedicine.4912-20

---

2752
diagnosis of platelet dysfunction was made, prophylactic platelet transfusion was administered to the patient, and invasive procedures could be performed safely. Additionally, a transjugular liver biopsy revealed that portal hypertension caused by extramedullary hematopoiesis in the liver had led to the onset of massive ascites.

At one month after admission, the patient underwent allo-HCT with the intention to suppress extramedullary hematopoiesis and obtain normal trilineage hematopoiesis. Neutrophil engraftment was achieved at 46 days after allo-HCT, whereas platelet engraftment was not achieved before he expired, namely at 112 days after allo-HCT due to idiopathic pneumonia syndrome. Therefore, platelet transfusion could not be stopped by performing allo-HCT in the present case.

### Discussion

We herein describe a case of acquired platelet dysfunction that mimicked gray platelet syndrome (GPS) accompanied by CALR-mutated PMF. The detection of abnormal platelets, including large gray platelets, under light microscopy and the loss of the second wave of aggregation observed by LTA was an important clue for the diagnosis of platelet dysfunction, which was further confirmed by electron microscopy. In addition, prophylactic platelet transfusion could reduce the risk of bleeding in patients suffering from platelet dysfunction.

Morphologically unusual platelets with an abnormal function may be observed in CALR-mutated MPNs because thrombopoietin-independent megakaryopoiesis through the thrombopoietin receptor has been reported to be activated by mutant CALR (13). Another study reported that CALR-mutated platelets were less activated following ADP stimulation (14). They speculated that the result could explain the lower risk of thrombosis in CALR-mutated ET patients compared with JAK2-mutated ET patients. This result might partially account for the bleeding that occurred in the present case. In the present PMF case, there existed the possibility that platelet dysfunction due to a mutation in CALR and the development of an increased bleeding risk, which was compensated by his relatively high platelet count (31.0×10^9/μL) before cytoreductive therapy was started, might have occurred according to the decreasing platelet count. Our case suggests that we should examine the platelet function in MPN patients in order to assess the risk of bleeding if invasive procedures or cytoreductive therapies are planned.

Table 2. Coagulation Test Results.

| Variable                        | Reference range | After bleeding episodes |
|---------------------------------|-----------------|-------------------------|
| Bleeding time, Duke method (min) | 1.00-5.00       | 3.00                    |
| Prothrombin time (s)            | 11.5-14.5       | 13.0                    |
| PT-INR                          | 0.9-1.1         | 1.11                    |
| Activated partial-thromboplastin time (s) | 25.0-40.0 | 38.1                    |
| Fibrinogen (mg/dL)              | 200-400         | 468                     |
| FDP (μg/mL)                     | 0-10.0          | 20.7                    |
| TAT (ng/mL)                     | <3.0            | 1.8                     |
| PIC (μg/mL)                     | <0.8            | 1.1                     |
| Antithrombin (%)                | 70-120          | 115                     |
| Protein C activity (%)          | 64-146          | 78                      |
| Protein S activity (%)          | 67-164          | 59                      |
| Factor II activity (%)          | 74-146          | 98                      |
| Factor V activity (%)           | 70-152          | 54                      |
| Factor VII activity (%)         | 63-143          | 107                     |
| Factor VIII activity (%)        | 80-140          | 95                      |
| Factor IX activity (%)          | 80-120          | 70                      |
| Factor X activity (%)           | 71-128          | 111                     |
| Factor XIII activity (%)        | 70-140          | 95                      |
| vWF:antigen (%)                 | 50-155          | 74                      |
| vWF:RCo (%)                     | 60-170          | 29                      |

FDP: fibrin and fibrinogen degradation products, PIC: plasmin-α2 plasmin inhibitor complex, PT-INR: prothrombin time international normalized ratio, RCo: ristocetin cofactor, TAT: thrombin-antithrombin complex.
Figure 1. Large gray platelets were observed with May-Giemsa staining under light microscopy (A and B). Electron microscopy demonstrated that platelets lacked α-granules (C) and contained abundant channels of the open canalicular system (D).

functions, among them platelet-interfering drugs, such as aspirin and thienopyridines, clonal hematopoiesis of MPNs, monoclonal protein, liver disease, uremia, cardiopulmonary bypass, and antiplatelet antibodies (17). In this case, the loss of the second wave of aggregation was attributed to the clonal hematopoiesis of MPNs that mimicked the congenital pathogenesis of platelet secretion disorders because the patient did not have liver disease except for extramedullary hematopoiesis and uremia without platelet-interfering drugs, monoclonal protein, cardiopulmonary bypass, and antiplatelet antibodies. Moreover, typical platelet secretion disorders showed a decreased aggregation response to collagen, as well as a loss of the second wave by ADP, but the hemostatic patterns of clonal hematopoiesis of MPNs were reported to be heterogeneous (7, 18).

GPS is an inherited platelet dysfunction disorder characterized by levels of platelet α-granules which are less than 15% of normal (19-21). Mutations in the genes encoding several proteins, such as NBEAL2, GATA1, and VPS33B/VIPS39, in arthrogryposis, renal dysfunction, and cholestasis syndrome, respectively, and GFI1B were reported to be responsible for GPS, although the mutation sites are heterogeneous (22, 23). The LTA pattern of GPS is reported to be heterogeneous, although a decreased aggregation response to collagen and the loss of the second wave by ADP are typical (18, 19, 24, 25). Therefore, the diagnosis of GPS was further confirmed morphologically by electron microscopy (26). Additionally, several reports have shown that congenital GPS can cause secondary myelofibrosis (25, 27). However, this PMF patient’s hemostatic disorder was not considered to be congenital because he had no family history of hemostatic disorders and had experienced no bleeding events before developing PMF. Based on these considerations, we thought that he had likely developed “acquired GPS” associated with PMF.

In this case, “acquired GPS” seemed to be the main cause of uncontrolled bleeding because prophylactic platelet transfusion prevented uncontrolled bleeding during invasive procedures; however, the possibility of concomitant AvWS was not completely ruled out owing to the decreased in vWF:
normal wave pattern of aggregation by LTA in samples collected with sodium citrate rather than EDTA, we confirmed the presence of large gray platelets by light microscopy and the absence of platelet α-granules by electron microscopy only in his EDTA sample. In order to make a more accurate diagnosis of “acquired GPS,” we require additional examinations, including genetic analyses and morphological findings on blood samples collected by using sodium citrate or heparin.

In conclusion, the detection of large gray platelets under light microscopy and abnormal wave patterns of aggregation by LTA may therefore be an important clue for the diagnosis of hemostatic disorders accompanied by MPNs. In addition, prophylactic platelet transfusion could reduce the risk of bleeding in patients suffering from platelet dysfunction. When morphologically unusual platelets are observed in MPN patients, platelet dysfunction disorders, including acquired GPS, should therefore be ruled out.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We thank Aya Ikemoto (Department of Central Clinical Laboratory, Osaka City University Hospital) for her valuable help in the laboratory data interpretation.
References

1. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93: 1551-1560, 2018.

2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, et al., Eds. Myeloproliferative neoplasms. Lyon, 2017: 29-60.

3. Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 12: 389-396, 2017.

4. Ke D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol 96: 1595-1604, 2017.

5. Appelmann I, Kreher S, Parmentier S, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol 95: 707-718, 2016.

6. Kander EM, Raza S, Zhou Z, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102: 587-593, 2015.

7. Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med 5: 79-87, 2001.

8. Takenaka K, Shimoda K, Uchida N, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol 105: 59-69, 2017.

9. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-397, 2011.

10. Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 125: 2029-2037, 2015.

11. Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013.

12. Baronciani L, Peyvandi F. How we make an accurate diagnosis of von Willebrand disease. Thrombosis Research Forthcoming.

13. Araki M, Yang Y, Masubuchi N, et al. Activation of the thromboxane receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 127: 1307-1316, 2016.

14. Hauschner H, Bokstad Horev M, Misgav M, et al. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2V617F mutated platelets. Am J Hematol Forthcoming.

15. Liverani E, Rico MC, Tsygankov AY, Kilpatrick LE, Kunapuli SP. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol 36: 961-971, 2016.

16. Bennett JS, Rao AK. Chapter 65. Inherited disorders of platelet function. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, Eds. Lippincott Williams & Wilkins, Philadelphia, PA, 2013.

17. Rao AK, Bennett JS. Chapter 66. Acquired disorders of platelet function. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Marder VJ, Aird WC, Bennett JS, Schuman S, White GC, Eds. Lippincott Williams & Wilkins, Philadelphia, PA, 2013.

18. Dovlatova N. Current status and future prospects for platelet function testing in the diagnosis of inherited bleeding disorders. Br J Haematol 170: 150-161, 2015.

19. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 21: 21-36, 2007.

20. Stevenson WS, Morel-Kopp MC, Ward CM. Platelets are not all gray in GFTIB disease. Clin Genet 87: 299, 2015.

21. Gerrard JM, Phillips DR, Rao GH, et al. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest 66: 102-109, 1980.

22. Nurden AT, Nurden P. Should any genetic defect affecting alpha-granules in platelets be classified as gray platelet syndrome? Ann Hematol 91: 714-718, 2016.

23. Bianchi E, Norfo R, Pennucci V, Zini R, Manfredini R. Genomic landscape of megakaryopoiesis and platelet function defects. Blood 127: 1249-1259, 2016.

24. Israels SJ. Laboratory testing for platelet function disorders. Int J Lab Hematol 37 (Suppl): 18-24, 2015.

25. Gunay-Aydin M, Zivyoni-Elboum Y, Gumruk F, et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 116: 4990-5001, 2010.

26. Baldini CL, Cattaneo M, Fabris F, et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 88: 582-592, 2003.

27. Guererro JA, Bennett C, van der, Weyden L, et al. Gray platelet syndrome: proinflammatory megakaryocytes and alpha-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood 124: 3624-3635, 2014.

28. Rottenstreich A, Kleinig N, Kharchevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocytopenia and polycythemia vera. Eur J Intern Med 41: 49-54, 2017.

29. Kaufman RM, Djalbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162: 205-213, 2015.

30. Briggs A, Gates JD, Kaufman RM, Calahan C, Gornley WB, Havens JM. Platelet dysfunction and platelet transfusion in traumatic brain injury. J Surg Res 193: 802-806, 2015.

31. Linnik YA, Salvatore LT, Lowrey CH, Ornestle DL. Severe acquired platelet dysfunction because of primary myelofibrosis with full functional and morphological recovery after allogeneic hematopoietic cell transplantation. Blood Coagul Fibrinolysis 30: 419-422, 2019.

32. Cockbill SR, Burmester HB, Hepstall S. Pseudo grey platelet syndrome - grey platelets due to degranulation in blood collected in EDTA. Eur J Haematol 41: 326-333, 1988.

33. Mant MJ, Doery JC, Gauldie J, Sims H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand J Haematol 15: 161-170, 1975.